278 Total Antioxidant Capacity, Hydrogen Peroxide, Malondialdehyde and Total Nitric Oxide Concentrations in Patients With Severe Persistent Allergic Asthma

Abstract

BackgroundThere is no data available to adequately explain the alterations in total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in severe persistent asthma and newly diagnosed allergic asthma patients. In the study below we have examined changes in total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide levels in severe persistent asthma and newly diagnosed allergic asthma patients and the association(s) between these variables.MethodsThe first group of patients included 6 male and 8 female subjects with severe persistent asthma, having a mean age of 42.4 years. A second group of subjects consisted of 14 newly diagnosed allergic asthma patients with a mean age of 43.8 years. All patients were followed in our clinic, and were evaluated by clinical status. A third group of 14 age-sex matched healthy controls were also included. Serum samples were collected and stored at –70 until use for the determination of total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations. Serum IgE levels, ANA, RF, hepatitis markers, C3, C4 and eosinophil levels were evaluated in all patients. All assays were carried out in duplicate.ResultsTotal antioxidant capacity levels of Group IB, group II and group III were lower than the IA group. Total antioxidant capacity levels of groups II and III were higher than in group IB. Hydrogen peroxide concentrations in group IB were lower than in group IA, while concentrations in group II were higher than in group IB. The malondialdehyde concentration of group IB was lower than in all other groups. The malondialdehyde concentration of group III was higher than all other groups. The malondialdehyde concentration of group II was lower than in group III. The total nitric oxide level of group IB was lower than all other groups. The total nitric oxide level of group III was higher than all other groups, while that of group II was higher than for both groups IA/IB.ConclusionsTo monitor the omalizumab treatment efficacy in the severe allergic asthma patients; total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations might be new markers.

IL-8, IL-10, TGF-β, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment

“…Further anti-inflammatory effects, including changes in interleukin levels, have been observed and postulated to contribute to the clinical efficacy of omalizumab treatment [20, 21]. Other studies in severe persistent allergic asthma patients receiving omalizumab therapy have focused on modulation of serum soluble TNF-related apoptosis-inducing ligand, total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations, and ceruloplasmin oxidase activity measurements, as markers of the efficacy of anti-IgE treatment modality [43–46]. Our data add IL-8, IL-10, TGF- β , and GCSF to this list.…”

Triphala (PADMA) extract alleviates bronchial hyperreactivity in a mouse model through liver and spleen immune modulation and increased anti-oxidative effects

“…Triphala's beneficial effect in a murine model of asthma can be caused by both an immunomodulatory effect as well as an anti-oxidative effect working in concert. Indeed the importance of increased oxidative burden in the pathogenesis of asthma is increasingly recognized [Yalcin et al 2012;Hox et al 2011;Celik et al 2012] suggesting that lowering the oxidative injury in asthmatic lungs can potentially lower airway hyperactivity. We have previously shown that Triphala's immunomodulatory effects are independent of its antioxidant properties [Horani et al 2011] suggesting that both the immunomodulation and anti-oxidative capacity observed in the bronchoalveolar fluid may indeed be synergic.…”

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

“…The most recent studies on severe persistent allergic asthma and the effect of omalizumab treatment, provided novel perspectives on using serum soluble TNF-related apoptosis inducing ligand, nitric oxide, malondialdehyde, hydrogen peroxide and albumin levels, total antioxidant capacity and ceruloplasmin activity as an efficacy marker [33][34][35][36].…”